[ ZAI Lab raises $30M in Series C ]
ZAI Lab has raised $30 million in Series C funding.
Founded in 2013, ZAI Lab is engaged in the research, development and commercialization of omadacycline for the treatment of autoimmune and infectious diseases.
The start-up plans to use the latest proceeds to invest in its research and development, as well as support future partnering activities.
|Founder / CEO||Samantha DU|
|Investors||Rock Springs Capital|
|Cormorant Asset Management|
|Previous Investors||TF Capital|
|Qiming Venture Partners|
|Kleiner Perkins Caufield & Byers|